ArticleCurrent ophthalmology reports2013
Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.
Article in Current ophthalmology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Article
- Hydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges.Materials (Basel, Switzerland) · 2023Review
- Diabetic Macular Oedema Guidelines: An Australian Perspective.Journal of ophthalmology · 2023Review
- Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema.Cost effectiveness and resource allocation : C/E · 2022Article
- Assessment of Patients' Confidence Regarding a New Triage Concept in a Medical Retina Clinic during the First COVID-19 Outbreak.International journal of environmental research and public health · 2021Article
- Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab.Journal of current ophthalmology · 2019Article
- Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice.Scientific reports · 2018Article
- Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.Journal of ophthalmology · 2018Article
- New Drugs and New Posterior Delivery Methods in CME.Current ophthalmology reports · 2017Article
- Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.Progress in retinal and eye research · 2017Review
- Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies.International journal of ophthalmology · 2017Article
- Update on corticosteroids for diabetic macular edema.Clinical ophthalmology (Auckland, N.Z.) · 2016Review
- Review
- Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant.Diabetes, metabolic syndrome and obesity : targets and therapy · 2015Review
- Sustained-release corticosteroid options.Journal of ophthalmology · 2014Review
- Impact of Prefilled Syringes and Masking on Postintravitreal Injection Endophthalmitis.Journal of vitreoretinal diseasesArticle
- Conbercept and Retinal Photocoagulation in the treatment of Diabetic Macular Edema.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Diabetic macular edema (DME) remains an important worldwide cause of visual loss. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with risks of infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration (FDA) for the treatment of DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.